Preclinical pharmacology of novel indolecarboxamide ML-970, an investigative anticancer agent

Cancer Chemotherapy and Pharmacology

Volumn 69, Issue 6, 2012, Pages 1423-1431

  Rayburn, Elizabeth ^a   Wang, Wei ^a,b   Li, Mao ^a   Zhang, Xu ^a,b   Xu, Hongxia ^a,b   Li, Haibo ^a   Qin, Jiang Jiang ^b   Jia, Lee ^c   Covey, Joseph ^c   Lee, Moses ^d   Zhang, Ruiwen ^a,b  

^a University of Alabama at Birmingham   (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d HOPE COLLEGE   (United States)

Author keywords

Enterohepatic circulation; HPLC; Indolecarboxamide; ML 970 (NSC 716970); Pharmacokinetics; Protein binding

Indexed keywords

AMIDE; ANTINEOPLASTIC AGENT; ML 970; N [4 AMINO 1 (2 CHLOROETHYL)NAPHTHALEN 2 YL] 5,6,7 TRIMETHOXY 1H INDOLE 2 CARBOXAMIDE; NSC 716970; RACHELMYCIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BONE MARROW TOXICITY; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG FECES LEVEL; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG STABILITY; DRUG URINE LEVEL; ENTEROHEPATIC CIRCULATION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; INCUBATION TIME; KIDNEY PARENCHYMA; LIVER PARENCHYMA; LUNG PARENCHYMA; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MOUSE; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; SMALL INTESTINE; STRAIN DIFFERENCE; TIME TO MAXIMUM PLASMA CONCENTRATION;

1-NAPHTHYLAMINE; ANIMALS; ANTINEOPLASTIC AGENTS; BLOOD PROTEINS; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG STABILITY; DRUGS, INVESTIGATIONAL; FEMALE; HUMANS; INDOLES; MICE; MICE, INBRED ICR; MICROSOMES, LIVER; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84863809407     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-012-1851-9     Document Type: Article

References (11)

1. Sato A, McNulty L, Cox K, Kim S, Scott A, Daniell K, Summerville K, Price C, Hudson S, Kiakos K, Hartley JA, Asao T, Lee M (2005) A novel class of in vivo active anticancer agents: achiral seco-amino- and seco- hydroxycyclopropylbenz[e]indolone (seco-CBI) analogues of the duocarmycins and CC-1065. J Med Chem 48:3903-3918
2. MacMillan KS, Lajiness JP, Cara CL, Romagnoli R, Robertson WM, Hwang I, Baraldi PG, Boger DL (2009) Synthesis and evaluation of a thio analogue of duocarmycin SA. Bioorg Med Chem Lett 19:6962-6965
3. Toth JL, Trzupek JD, Flores LV, Kiakos K, Hartley JA, Pennington WT, Lee M (2005) A novel achiral seco-amino-cyclopropylindoline (CI) analog of CC-1065 and the duocarmycins: design, synthesis and biological studies. Med Chem 1:13-19
4. Kiakos K, Sato A, Asao T, McHugh PJ, Lee M, Hartley JA (2007) DNA sequence selective adenine alkylation, mechanism of adduct repair, and in vivo antitumor activity of the novel achiral seco-amino-cyclopropylbenz[e]indolone analogue of duocarmycin AS-I-145. Mol Cancer Ther 6:2708-2718
5. Agrawal S, Zhang X, Cai Q, Kandimalla ER, Manning A, Jiang Z, Marcel T, Zhang R (1998) Effect of aspirin on protein binding and tissue disposition of oligonucleotide phosphorothioate in rats. J Drug Target 5:303-312
6. Wang H, Wang Z, Wang S, Li M, Nan L, Rhie JK, Covey JM, Zhang R, Hill DL (2005) Preclinical pharmacology of epothilone D, a novel tubulin-stabilizing antitumor agent. Cancer Chemother Pharmacol 56:255-260
7. Wang H, Li M, Rhie JK, Hockenbery DM, Covey JM, Zhang R, Hill DL (2005) Preclinical pharmacology of 2-methoxyantimycin A compounds as novel antitumor agents. Cancer Chemother Pharmacol 56:291-298
8. Ivy SP, Siu LL, Garrett-Mayer E, Rubinstein L (2010) Approaches to phase 1 clinical trial design focused on safety, efficiency, and selected patient populations: a report from the clinical trial design task force of the national cancer institute investigational drug steering committee. Clin Cancer Res 16:1726-1736
9. Paxton JW (1995) The allometric approach for interspecies scaling of pharmacokinetics and toxicity of anti-cancer drugs. Clin Exp Pharmacol Physiol 22:851-854
10. Bernillon P, Bois FY (2000) Statistical issues in toxicokinetic modeling: a bayesian perspective. Environ Health Perspect 108(Suppl 5):883-893
11. Smith DA, Obach RS (2009) Metabolites in safety testing (MIST): considerations of mechanisms of toxicity with dose, abundance, and duration of treatment. Chem Res Toxicol 22:267-279